A detailed history of Bank Of America Corp transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 327,233 shares of CARA stock, worth $85,080. This represents 0.0% of its overall portfolio holdings.

Number of Shares
327,233
Previous 477,683 31.5%
Holding current value
$85,080
Previous $124,000 18.55%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.26 - $0.38 $39,117 - $57,171
-150,450 Reduced 31.5%
327,233 $101,000
Q2 2024

Aug 14, 2024

SELL
$0.24 - $0.92 $38,051 - $145,863
-158,547 Reduced 24.92%
477,683 $124,000
Q1 2024

May 15, 2024

SELL
$0.52 - $1.05 $4,465 - $9,016
-8,587 Reduced 1.33%
636,230 $578,000
Q4 2023

Feb 14, 2024

SELL
$0.6 - $1.65 $98,950 - $272,113
-164,917 Reduced 20.37%
644,817 $477,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $4.94 $138,341 - $241,486
48,884 Added 6.42%
809,734 $2.29 Million
Q1 2023

May 12, 2023

BUY
$4.89 - $12.27 $440,031 - $1.1 Million
89,986 Added 13.41%
760,850 $3.74 Million
Q4 2022

Feb 10, 2023

BUY
$8.88 - $12.77 $5.42 Million - $7.79 Million
610,395 Added 1009.43%
670,864 $7.21 Million
Q3 2022

Nov 14, 2022

BUY
$8.24 - $12.56 $208,208 - $317,366
25,268 Added 71.78%
60,469 $565,000
Q2 2022

Aug 12, 2022

SELL
$7.45 - $13.84 $200,963 - $373,334
-26,975 Reduced 43.38%
35,201 $321,000
Q1 2022

May 16, 2022

SELL
$9.94 - $12.65 $279,443 - $355,629
-28,113 Reduced 31.14%
62,176 $756,000
Q4 2021

Feb 08, 2022

BUY
$11.99 - $18.14 $225,495 - $341,158
18,807 Added 26.31%
90,289 $1.1 Million
Q3 2021

Nov 15, 2021

SELL
$11.55 - $16.06 $1.46 Million - $2.02 Million
-126,065 Reduced 63.82%
71,482 $1.1 Million
Q2 2021

Sep 13, 2021

BUY
$12.38 - $29.19 $2.45 Million - $5.77 Million
197,547 New
197,547 $2.82 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.